Pancreatic Cancer Research

ResearcherUniversity of JordanActive in the last 2 years

Mohammad Abu Hilal

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3162-4639; OpenAlex author ID A5013484531, A5083141549. Sources: ClinicalTrials.gov.

Their work

Papers
36 (first author 1, last author 5)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
169
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 6 papers · 2021: 6 papers · 2022: none · 2023: 6 papers · 2024: 4 papers · 2025: 1 paper, 1 trial · 2026: 3 papers

Papers 36

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  3. Splenic hilum nodal involvement in resected left-sided pancreatic cancer: meta-analysis. Co-author DOI 10.1093/bjsopen/zrag153↗
  4. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  5. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  6. The pan - COVID - AGICT study. The impact of COVID-19 pandemic on surgically treated pancreatic cancer patients. A multicentric Italian study. Co-author DOI 10.1016/j.suronc.2024.102081↗
  7. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  8. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  9. Minimally invasive versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: Individual patient data meta-analysis of randomized trials. Co-author DOI 10.1016/j.ejso.2023.03.227↗
  10. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  11. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  12. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  13. ASO Author Reflections: The Safety and Efficacy of Robot-Assisted and Laparoscopic Distal Pancreatectomy in Patients with Resectable Left-Sided Pancreatic Canc… Co-author DOI 10.1245/s10434-023-13171-6↗
  14. Robot-Assisted versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International Retrospective Cohort Study-Authors' Re… Co-author DOI 10.1245/s10434-023-13545-w↗
  15. Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study. Co-author DOI 10.1007/s00464-020-08206-y↗
  16. Resectability of Pancreatic Cancer Is in the Eye of the Observer: A Multicenter, Blinded, Prospective Assessment of Interobserver Agreement on NCCN Resectabili… Co-author DOI 10.1097/as9.0000000000000087↗
  17. Outcomes of Elective and Emergency Conversion in Minimally Invasive Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: An International Multicenter Pr… Last author DOI 10.1097/sla.0000000000003717↗
  18. Response to Comment on "Outcomes of Elective and Emergency Conversion in Minimally Invasive Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: An Inte… Last author DOI 10.1097/sla.0000000000004279↗
  19. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Last author DOI 10.1186/s13063-021-05506-z↗
  20. Predictors for Survival in an International Cohort of Patients Undergoing Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08658-5↗
  21. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  22. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.12.023↗
  23. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Sco… Last author DOI 10.1245/s10434-019-08137-6↗
  24. ASO Author Reflections: Surgical Predictors for Survival in Patients Undergoing Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-020-08911-x↗
  25. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data. Last author DOI 10.3389/fonc.2020.01112↗
  26. Laparoscopic Radical Left Pancreatectomy for Pancreatic Cancer: Surgical Strategy and Technique Video. Co-author DOI 10.3791/60332↗
  27. Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ejso.2018.12.003↗
  28. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2018.3617↗
  29. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-gluco… Co-author DOI 10.3310/hta22070↗
  30. Impact of portal vein infiltration and type of venous reconstruction in surgery for borderline resectable pancreatic cancer. Co-author DOI 10.1002/bjs.10580↗
  31. Cost-effectiveness of laparoscopic versus open distal pancreatectomy for pancreatic cancer. Co-author DOI 10.1371/journal.pone.0189631↗
  32. Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: results of a multicenter cohort study on 196 patients. Co-author DOI 10.1007/s00464-015-4623-x↗
  33. Laparoscopic radical 'no-touch' left pancreatosplenectomy for pancreatic ductal adenocarcinoma: technique and results. Co-author DOI 10.1007/s00464-015-4685-9↗
  34. Pancreatic cancer tissue banks: where are we heading? Co-author DOI 10.2217/fon-2016-0243↗
  35. Outcome after pancreaticoduodenectomy for T3 adenocarcinoma: A multivariable analysis from the UK Vascular Resection for Pancreatic Cancer Study Group. Co-author DOI 10.1016/j.ejso.2015.08.158↗
  36. Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study. Co-author DOI 10.1016/j.jamcollsurg.2013.11.017↗

Trials 1

  1. Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3) Principal investigator NCT06939023↗

Closest collaborators

The 25 strongest of 169 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 20 shared papers, 1 shared trial, 2016–2026 · strength 3.62
  2. Maarten Korrel · 9 shared papers, 2019–2024 · strength 1.12
  3. Jony van Hilst · 8 shared papers, 2019–2026 · strength 1.11
  4. Sanne Lof · 9 shared papers, 2018–2023 · strength 0.97
  5. Bas Groot Koerkamp · 8 shared papers, 2018–2026 · strength 0.83
  6. Giuseppe Malleo · 7 shared papers, 2018–2026 · strength 0.82
  7. Ugo Boggi · 7 shared papers, 2020–2024 · strength 0.73
  8. Thilo Hackert · 6 shared papers, 2020–2026 · strength 0.70
  9. Tobias Keck · 7 shared papers, 2020–2024 · strength 0.67
  10. Tess M. E. van Ramshorst · 3 shared papers, 2023 · strength 0.64
  11. Jeffrey W. Chen · 3 shared papers, 2023 · strength 0.64
  12. Giovanni Butturini · 6 shared papers, 2020–2024 · strength 0.60
  13. Massimo Falconi · 6 shared papers, 2020–2024 · strength 0.58
  14. Adnan A. Alseidi · 6 shared papers, 2020–2024 · strength 0.56
  15. Bjørn Edwin · 6 shared papers, 2016–2023 · strength 0.55
  16. Alessandro Zerbi · 5 shared papers, 2020–2024 · strength 0.54
  17. Safi Dokmak · 5 shared papers, 2020–2024 · strength 0.53
  18. Riccardo Casadei · 5 shared papers, 2020–2024 · strength 0.51
  19. Jin‐Young Jang · 4 shared papers, 2020–2026 · strength 0.48
  20. Matteo De Pastena · 5 shared papers, 2018–2024 · strength 0.47
  21. C.L. Bruna · 2 shared papers, 2024–2026 · strength 0.47
  22. Roberto Salvia · 5 shared papers, 2018–2024 · strength 0.44
  23. Casper H.J. van Eijck · 4 shared papers, 2018–2026 · strength 0.43
  24. Claudio Bassi · 5 shared papers, 2018–2021 · strength 0.42
  25. Gianpaolo Balzano · 4 shared papers, 2020–2024 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.